Tuesday - April 29, 2025
DENVER, June 05, 2023 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced that Patrick Blair, president and CEO, and Barbara Gutierrez, CFO will be speaking at the 44th Annual Goldman Sachs Healthcare Conference on Wednesday, June 14, 2023, at 9:20 a.m. (PT) / 12:20 p.m. (ET). The event will be webcast live, and a link for the event will be available online on the investor relations section of the Company’s website.
About InnovAge
InnovAge is a market leader in managing the care of high-cost, dual-eligible seniors. Our mission is to enable seniors to age independently in their own homes for as long as safely possible. Our patient-centered care model is designed to improve the quality of care our participants receive, while reducing over-utilization of high-cost care settings. InnovAge believes its healthcare model is one in which all constituencies — participants, their families, providers and government payors — “win.” As of March 31, 2023, InnovAge served approximately 6,310 participants across 17 centers in five states. https://www.innovage.com/.
Investor Contact:
Ryan Kubota
rkubota@myinnovage.com
Media Contact:
Lara Hazenfield
lhazenfield@innovage.com
Last Trade: | US$3.11 |
Daily Change: | 0.06 1.97 |
Daily Volume: | 22,680 |
Market Cap: | US$421.280M |
February 04, 2025 November 05, 2024 November 04, 2024 October 11, 2024 September 16, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load